Tofacitinib(Biora Therapeutics)

N/A

Report date: 2024/05/07 15:21:05

Base Information

Drug NameTofacitinib(Biora Therapeutics)
Drug Alias NameBT-600PGN-600
ClassificationSmall molecules > Heterocyclic drugsDrug and medical devices combination products
Mechanisms of ActionTyrosine-protein kinase JAK1 inhibitorsTyrosine-protein kinase JAK2 inhibitorsTyrosine-protein kinase JAK3 inhibitors
TargetsTyrosine-protein kinase JAK1Tyrosine-protein kinase JAK2Tyrosine-protein kinase JAK3
Therapy Area/IndicationsColitis, Ulcerative
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesProgenity Inc
China Registration ClassN/A

Develop Information

Active CompaniesBiora Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsColitis, Ulcerative
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A